Opendata, web and dolomites

RESOLVE SIGNED

tPA-Nanoconstructs for Treating Acute Ischemic Stroke: a Technical and Commercial Analysis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESOLVE project word cloud

Explore the words cloud of the RESOLVE project. It provides you a very rough idea of what is the project "RESOLVE" about.

fast    causing    dpns    disabilities    5m    suffering    nanoconstructs    nano    approved    indirect    longer    cohort    administered    50    20b    statistics    clinically    total    agents    economic       complications    small    emotional    secured    cerebral    validated    validating    alleviate    administration    safer    commercial    estimate    markets    therapeutic    direct    moved    productivity    ischemic    death    considerable    lasting    17m    neurotoxicity    drug    designed    damage    faster    thrombectomy    lost    stroke    6m    thorough    combination    profile    strokes    patent    limitations    pharmaceutical    molecule    investing    fda    models    clot    dissolution    treatments    protocols    people    whereas    efficacy    occlusion    toxic    profiles    thrombolytic    worldwide    survivors    discoidal    medical    business    vessels    induces    market    excretion    deaths    circulation    societal    25b    thrombolysis    diminish    sale    companies    burden    biodegradation    healthcare    portfolio    neurological    re    stability    rationally    interaction    fabrication    therapies    diagnostics    revolutionize    polymeric    clots    patients    acute    blood    tech    brain    economical    safely    reports    tpa   

Project "RESOLVE" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA 

Organization address
address: VIA MOREGO 30
city: GENOVA
postcode: 16163
website: www.iit.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA IT (GENOVA) coordinator 150˙000.00

Map

 Project objective

Acute ischemic strokes result from the occlusion of cerebral vessels by blood clots causing neurological complications, brain damage and death. Based on WHO reports, stroke affects 17M people per year worldwide, with 6M deaths and 5M survivors suffering long-lasting disabilities. Recent statistics estimate an EU direct healthcare cost for stroke of €20B and indirect costs, due to disabilities and lost productivity, of €25B. The two current treatments – thrombolysis and thrombectomy – come with limitations and considerable side effects. Thrombolysis can be safely administered only to a small cohort of patients (about 5%) whereas thrombectomy induces disabilities in 50% of the cases. Moved by the societal, economical, and emotional burden associated with stroke, this proposal aims at developing and validating more effective and less toxic therapies via the combination of the clinically approved molecule tPA and rationally-designed, discoidal polymeric nanoconstructs (DPNs). As compared to tPA, the proposed thrombolytic nano-agents (tPA-DPNs) are expected to provide faster blood clot dissolution; safer administration profile; longer blood circulation and stability. On the technical side, tPA-DPNs will be re-designed to improve their biodegradation and excretion profiles; validated in FDA-recognized stroke models for neurotoxicity and therapeutic efficacy. On the commercial side, a patent portfolio covering the fabrication and utilization of tPA-DPNs will be secured, together with thorough market and business analyses. This will facilitate the interaction with pharmaceutical companies that are investing in the fast growing markets of high-tech drug delivery systems and stroke diagnostics and therapies. tPA-DPNs are expected to alleviate the economic burden on healthcare systems, increase the total sale of thrombolytic agents, revolutionize the medical protocols for stroke management, and diminish the societal and emotional impact of stroke.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESOLVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESOLVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

EVOMENS (2020)

The evolution of menstruation in primates

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More